A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Inclusion Criteria:

• Diagnosis of probably Alzheimer's disease for at least 1 year.
• Mini Mental State Exam (MMSE) score between 12-26 at screening.
• Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months.

Exclusion Criteria:

• Current evidence of a neurological or psychiatric illness that could contribute to dementia.
• Living alone.
• Poorly controlled high blood pressure.